Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 13, Issue 6, Pages 643-652Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543784.13.6.643
Keywords
cyclic guanosine monophosphate; heart failure; natriuretic pepticles; nesiritide; neurohumoral activation
Categories
Funding
- NHLBI NIH HHS [HL-36634] Funding Source: Medline
Ask authors/readers for more resources
Atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) are secreted by the heart and play important roles in the compensation of congestive heart failure with their vasodilating, natriuretic, antiproliferative, lusitropic and neurohumoral-modulating properties. Based on these beneficial properties, exogenous BNP was developed as a new treatment for congestive heart failure and approved in the US for acute decompensated heart failure. New therapeutic strategies for heart failure that are currently being investigated include chronic subcutaneous BNP administration and intermittent BNP infusions. Furthermore, strategies combining exogenous BNP with an inhibitor of the BNP-degrading enzyme neutral endopeptidase could contribute to maximising the actions of BNP and reduce the amount of exogenous BNP needed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available